Usoro Immunological: Kedu ka Alleles si skew na MHC Class I Ligandome
N'ọkwa molekul, psoriatic ogbu na nkwonkwo nwere njikọ siri ike na kpọmkwem HLA Class I susceptibility alleles, Kachasị mma HLA-C06:02, HLA-B27, HLA-B13, na HLA-B57. Nyochaa n'ime peptide na-ejikọta cleft polymorphism ọmụmụ (2020) na-egosi na nhụsianya dị na PsA na-akpali nke ukwuu site na njirimara nhazi nkekọrịta n'ofe HLA peptide-binding groove-kpọmkwem usoro dị iche iche nke ụgwọ ọjọọ na akpa B na polymorphic residues na ọnọdụ. 97.
Ihe owuwu ụlọ a na-agbanwe n'ụzọ bụ isi na-agbanwe mmachi nke molekul MHC Class I. Kama igosipụta sara mbara, homeostatic cross-ngalaba nke cellular proteome, susceptibility allotypes na-ahọrọ na-eme ka onwe-peptides nwere ihe ndị bụ isi, dị ka arginine na ọnọdụ 2 (P2) ma ọ bụ ọnọdụ 3 (P3). Mgbe ejikọtara ya na ọrịa metụtara ụdị nke antigen na-eme aminopeptidases (ERAP1 na ERAP2), dị ka pụta ìhè na Nkwekọrịta EULAR na MHC-I-opathies (2023), Igwe na-arụ ọrụ antigen nke cell na-emepụta peptidome gbagọrọ agbagọ.
|
Ihe |
Nkọwa |
|---|---|
|
Nhazi nkịtị |
Proteome Homeostatic dị iche iche → HLA-I Ligandome anaghị agba nchara → Nnwerekwa mgbochi |
|
Obodo Ọrịa PsA |
Ihe nhụsianya HLA Allotypes + Ụdị ERAP → Skewed P2/P3 Arginine-Rich Ligandome → CD8+ T na-arụ ọrụ cell arụ ọrụ |
N'ime anụ ahụ synovial na saịtị entheseal, Ngosipụta ngosi a na-ebute oke nnochi anya nke peptides autoantigenic kpọmkwem-dị ka iberi ndị sitere na protein ndị metụtara melanocyte dị ka ADAMTSL5 ma ọ bụ protein protein matriks akọwapụtara nke cartilage.. Ndị a na-egosipụta onwe-peptides na-etinye aka na sel CD8+ T autoreactive, na-akpalite mpaghara mkpali cascades na mbibi anụ ahụ.
Maka ndị nchọpụta biopharma, ịkọwapụta mgbanwe ngosi ndị a dị aghụghọ - nke na-emetụta obere mkpụkọ-mgbanwe na ngosipụta peptide ọkwa femtomole - dị mkpa iji chọpụta ma onye na-ahụ maka ọgwụgwọ na-eweghachi nguzozi ligandome nke ọma ma ọ bụ na-ahọrọ nke na-egbochi ihe ngosi peptide pathogenic..
Ihe kpatara na-achọghị nchọpụta Proteomics anaghị akọwapụta mgbanwe ngosi
Iji tụọ ihe ngosi HLA Klas I, Nchoputa nke mbido gbadoro ụkwụ siri ike na nweta data dabere na data echereghị (DDA) Mmiri chromatography-tandem mass spectrometry (LC-MS/MS). Ọ bụ ezie na DDA bara uru maka eserese qualitative nke mbụ, ọ na-egosipụta oke nhazi dị oke mkpa mgbe etinyere ya na ọmụmụ ntụgharị asụsụ ọnụọgụ:
-
Nlele stochastic na ọnụ ahịa bara uru dị elu: Na DDA, Mass spectrometer na-ahọpụta ion precursor kacha sie ike maka nkewa na okirikiri ọrụ ọ bụla.. N'ihi na HLA Class I peptides bụ ndị na-abụghị tryptic, nnukwu mgbanwe n'ogologo (na-emekarị 8 ka 11 amino asịd), ma dị ugbu a n'ụba dị oke ala (femtomoles kwa milligram nke anụ ahụ ma ọ bụ mbipụta kwa cell), A na-atụkarị peptides pathogenic obere n'ofe ndị otu ụlọọgwụ, na-ekweta na-efu-uru ọnụego nke 40% ka 60%.
-
Enweghị arịlịka ọnụọgụ zuru oke: Ọnụ ọgụgụ kacha elu DDA ejikọtaghị nke ọma na ọnụọgụ nnomi n'elu cell zuru oke. Enweghị ụkpụrụ isotopic dabara adaba, ntụgharị okwu aghụghọ (eg., mmụba okpukpu 2.5 na peptide autoantigenic) enweghị ike ịmata ọdịiche dị na matriks na-ebute mgbanwe ionization ma ọ bụ mfu njikwa ihe nlele.
-
Artifacts sitere na Peptides omenala dị oke mma: Ịkwado hits immunopeptidomic chọrọ ntụnye aka peptide sịntetik. Agbanyeghị, ọkọlọtọ crude agụmakwụkwọ-ọkwa sịntetik peptides (70% ka 80% ịdị ọcha) na-ebu nnukwu ihe adịghị ọcha. Mfọdụ trifluoroacetate (TFA) counter-ions na-eme ka ionization electrospray siri ike (ESI) na-emenyụ, ebe ezughị ezu deprotection byproducts na-emepụta akara mmalite adịgboroja nke na-agbagọ izi ezi nke ọnụọgụgụ.
Ntugharị igodo: Proteomics DDA na-echeghị eche dị mma maka nchọpụta ligand mbụ, mana nkwado ntụgharị asụsụ chọrọ nyocha LC-MS/MS ezubere iche gbadoro site na peptides sịntetik omenala dị ọcha yana ụkpụrụ isotopic siri ike kwụgidere..
Strategic dị mkpa: Usoro ọrụ Immunopeptidomics jikọtara ọnụ
Iji nweta nhịahụ nyocha achọrọ maka nkwado ebumnuche IND na-enyere aka, Otu nyocha ntụgharị asụsụ na-atụgharị gaa na ụdị LC-MS/MS ezubere iche—dị ka nleba anya mmeghachi omume ahọpụtara (SRM), Nleba anya mmeghachi omume yiri (PRM), yana Ọkọlọtọ Ime-kpaliri PRM (IS-PRM). Ime nlebanya ndị a dị elu na-achọ usoro ọrụ ogidi atọ agbakwunyere nke ọma.
|
Ogidi ọrụ |
Ngwa akụrụngwa |
Ọrụ Strategic na Immunopeptidomics |
|---|---|---|
|
Ọgwụ 1: Omenala Peptide Panels |
Ntinye dị elu, ọba akwụkwọ peptide mara nke ọma |
Na-enye ntụaka ọkụ sịntetik dabara amụma HLA ligands ma ọ bụ achọpụtara maka njigide oge na ụlọ ọbá akwụkwọ MS/MS spectral. |
|
Ọgwụ 2: Ụkpụrụ SIL dị arọ |
peptides nke akpọrọ isootope kwụsiri ike na-agụnye ^{13}C₆, ^{15}N₄ Arg ma ọ bụ ^{13}C₆, ^{15}N₂ Ndepụta |
Na-eje ozi dị ka ezigbo arịlịka ime ime, na-eme ka nha nha mgbanwe mpịaji dị n'ụzọ ziri ezi yana njiri elu cell zuru oke. |
|
Peptide Synthesis Ọgwụ 3: Nkwado Mmepe Assay |
Precursor mwepu enyo kachasị, net peptide nhazi nhazi, mgbanwe counter-ion |
Na-egbochi nnyonye anya isobaric, na-ewepu TFA ion suppression, ma na-eme ka ogbe-na-ogbe nyocha nrụpụtagharị. |
1. Panels Peptide omenala ezubere iche
Immunomic ntụgharị na-amalite site na paịlị ebumnuche ahaziri ahazi dabara na peptidome metụtara ọrịa.. Maka nyocha PSA, ogwe ga-ekpuchi HLA-C kpọmkwem06:02 na HLA-B27 ejigide motifs. Iji usoro ikpo okwu pụrụ iche dị ka Omenala Peptide Synthesis na-eme ka o doo anya na a na-emepụta peptides sịntetik na nkwesị ntụkwasị obi n'usoro, njikwa ogologo ogologo, na ịdị ọcha dị elu (≥ 95%), na-enye ọba akwụkwọ ntụaka pụrụ ịdabere na ya maka inweta LC-MS/MS.
2. Isotope kwụsiri ike—Akara aha (SIL) Ụkpụrụ ime
Ịgụ ihe ngosi na-agbanwe nke ọma, A na-atụba peptides dị arọ sịntetik n'ime ihe nlele HLA ligand immunopurified tupu nyocha LC-MS/MS.. Site na itinye isotopes dị arọ kwụsiri ike (^{13}C na ^{15}N) banye C-terminal ihe fọdụrụnụ (dị ka Arginine dị arọ [+10 Na] ma ọ bụ Lysine dị arọ [+8 Na]), ọkọlọtọ dị arọ na-egosipụta oge njide chromatographic yiri ya, ionization arụmọrụ, na omume nkewa dị ka eriri ọkụ endogenous.
Dị ka nkọwa zuru ezu na nyocha na Ezubere iche IS-PRM immunopeptidomics workflows (2024), itinye aka Isotope akpọrọ Peptides na-enye ohere ka spectrometers uka kpalite ngwa ngwa inweta ebumnuche, na-ewepụ mmetụta matriks ma na-eme ka ọnụọgụgụ enwere ike imepụtaghachi ruo ọkwa otu-attomole.
3. Mmepe Assay Raara Onwe & Nkwado ogo
Ụkpụrụ SIL dị elu naanị ezughi oke ma ọ bụrụ na eleghara ihe kemịkalụ anụ ahụ anya:
-
Nyocha ọdịnaya Peptide Net: Arọ peptide sịntetịt nwere ma peptide dị ọcha na mmiri agbụ ma ọ bụ ion counter-ion. Na-enweghị ezigbo mkpebi ọdịnaya peptide net (site na nyocha amino acid ma ọ bụ mkpebi nitrogen), ngụkọta ọnụ ọgụgụ zuru oke na-ebu njehie ruru 30%.
-
Mgbanwe TFA-to-Acetate Counter-ion: Ọkọlọtọ siri ike-phase peptide njikọ hapụrụ TFA fọdụrụnụ, reagent ion-pairing siri ike nke na-emenyụ akara electrospray na nanoLC-MS. Ime mgbanwe counter-ion na acetate ma ọ bụ nnu hydrochloride na-eweghachi uche MS.
-
Atụmatụ Mkpokọta Window Precursor: Ịmepụta akụkụ SIL ezubere iche chọrọ nleba anya m/z ngụkọ iji hụ na ụkpụrụ dị arọ adaghị n'ime mpio kewapụrụ iche. (na-emekarị ±1 m/z) nke nyocha panel ndị ọzọ ma ọ bụ adịghị ọcha na-enweghị akara.
Maka ndụmọdụ: Na-enyocha nkọwapụta counter-ion mgbe niile yana ọdịnaya peptide net tupu ịgbasa ụkpụrụ SIL n'ime ihe nlele ọgwụ mgbochi dị oke ọnụ ahịa.. Na-enyocha ntuziaka zuru oke na Peptides sịntetik rel=”soro” klaasị=”njikọ” href=”https://molchanges.com/beyond-the-coa-third-party-peptide-testing-audit-guide.html">Nnwale Peptide na nkwenye dị mma na-enyere aka hụ na nkwụsi ike nyocha nke batch-to-batch.
Na-eme ngwa ngwa nkwado biomarker na mmepe usoro ihe ọmụmụ dị mma
Ịnabata ụdị ọrụ immunopeptidomics agbakwunyere agbakwunyere na-ewepụta uru azụmahịa na sayensị kpọmkwem maka biopharma R&D otu:
-
Nkwado Biomarker siri ike: Ndị otu ntụgharị asụsụ nwere ike nyochaa akara nrịbama otu akụkụ n'ofe ndị otu ndị ọrịa ogologo oge, guzobe ọnụ ụzọ ọnụọgụ maka ọrụ ọrịa, nzaghachi ọgwụgwọ, ma ọ bụ nlọghachi azụ na ọrịa ogbu na nkwonkwo psoriatic. Mmepụta Peptide
-
TCR na-adịghị ize ndụ-dị ka Biologics na ọgwụgwọ Peptide-HLA: Usoro ihe ọmụmụ ihe ndụ emebere iji lekwasịrị anya ogige peptide-MHC akọwapụtara (eg., TCR-dị ka ọgwụ mgbochi ọrịa ma ọ bụ bispecific T-cell njikọ) chọrọ ihe akaebe zuru oke nke njupụta ngosi ebumnuche. Ntụle dabere na SIL ezubere iche na-ewepụta nọmba nnomi sel-elu nke achọrọ maka nrụpụta ọgwụgwọ..
-
Nleba anya Nchekwa Ezubere na Akwụsịghị: Site n'ịkọwa ihe ngosi mmalite n'ofe anụ ahụ ahụike na-abụghị ebumnuche, Ndị na-emepụta biopharma nwere ike nyochaa ihe nwere ike imeghachi omume n'oge na-adịghị anya n'oge mmepe izizi, na-ezere ọdachi autoimmune toxicities n'ime ule ụlọ ọgwụ.
Mmekọrịta ya na Platform Peptide pụrụ iche maka ịga nke ọma ntụgharị asụsụ
Ịkọpụta ihe ngosi MHC skewed nke klas I peptide na ọrịa ogbu na nkwonkwo na-achọ njikọ na-enweghị nkebi n'etiti kemịkalụ peptide na quantitative mass spectrometry.. Ndị na-ere katalọgụ reagent na-enwekarị njikwa mma pụrụ iche-dị ka klaasị 100 gburugburu njikọ njikọ ultra-sterile, akwadoro ọdịnaya peptide net, na ntụgharị TFA-to-acetate-chọrọ maka immunopeptidomics dị elu.
Site n'iji ike Ọrụ Peptide zuru oke sitere na ọkachamara R&D ndị mmekọ dị ka MOL Mgbanwe, Ndị na-eme mkpebi biopharma na-enweta ohere ozugbo na nhazi usoro omenala, njikọ ọkọlọtọ SIL dị elu dị elu, gafere 300 mgbanwe ọrụ, na nkwado mmepe nke ndị ọkà mmụta sayensị na ndị ọkà mmụta sayensị.
Ma ndị otu gị na-akwado ebumnuche autoimmune ọhụrụ, Immunopeptidomes pụrụ iche nke ọrịa, ma ọ bụ nyochaa ndu ndu bayoloji maka mmeghachi omume cross-reactivity, peptide omenala agbakwunyere na usoro SIL ọkọlọtọ na-enye nkọwa doro anya dị mkpa iji gaa n'ihu na nchekwa, ọgwụgwọ dị irè nke ukwuu n'ime ụlọ ọgwụ.
